Francesco Maura, MD, on Clinical Issues: Resistance in Newly Diagnosed Multiple Myeloma Treated With Targeted Immunotherapy

Posted: Sunday, December 11, 2022

Francesco Maura, MD, of the University of Miami, Sylvester Comprehensive Cancer Center, discusses patients with newly diagnosed multiple myeloma whose disease appears to be resistant even to multiple-agent combination treatment regimens. Dr. Maura’s team has identified a comprehensive list of genomic determinants of response to treatment and talks about the factors that may lead to poorer outcomes for 30% to 40% of patients whose disease progresses and does not sustain measurable residual disease negativity.